Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001711279-25-000021
Filing Date
2025-04-03
Accepted
2025-04-03 16:38:11
Documents
20
Period of Report
2025-04-03

Document Format Files

Seq Description Document Type Size
1 DEF 14A krys-20250403.htm   iXBRL DEF 14A 927630
3 krys-20250403_g1.jpg GRAPHIC 6734
4 krys-20250403_g2.jpg GRAPHIC 71390
5 krys-20250403_g3.jpg GRAPHIC 75145
6 krys-20250403_g4.jpg GRAPHIC 71701
7 krys-20250403_g5.jpg GRAPHIC 51176
8 krys-20250403_g6.jpg GRAPHIC 438477
9 krys-20250403_g7.jpg GRAPHIC 186295
  Complete submission text file 0001711279-25-000021.txt   3788132

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT krys-20250403.xsd EX-101.SCH 928
22 EXTRACTED XBRL INSTANCE DOCUMENT krys-20250403_htm.xml XML 232580
Mailing Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203
Business Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203 (412) 586-5830
Krystal Biotech, Inc. (Filer) CIK: 0001711279 (see all company filings)

EIN.: 821080209 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38210 | Film No.: 25810183
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)